Cargando…
Proteomics of CKD progression in the chronic renal insufficiency cohort
Progression of chronic kidney disease (CKD) portends myriad complications, including kidney failure. In this study, we analyze associations of 4638 plasma proteins among 3235 participants of the Chronic Renal Insufficiency Cohort Study with the primary outcome of 50% decline in estimated glomerular...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564759/ https://www.ncbi.nlm.nih.gov/pubmed/37816758 http://dx.doi.org/10.1038/s41467-023-41642-7 |
_version_ | 1785118546317017088 |
---|---|
author | Dubin, Ruth F. Deo, Rajat Ren, Yue Wang, Jianqiao Zheng, Zihe Shou, Haochang Go, Alan S. Parsa, Afshin Lash, James P. Rahman, Mahboob Hsu, Chi-yuan Weir, Matthew R. Chen, Jing Anderson, Amanda Grams, Morgan E. Surapaneni, Aditya Coresh, Josef Li, Hongzhe Kimmel, Paul L. Vasan, Ramachandran S. Feldman, Harold Segal, Mark R. Ganz, Peter |
author_facet | Dubin, Ruth F. Deo, Rajat Ren, Yue Wang, Jianqiao Zheng, Zihe Shou, Haochang Go, Alan S. Parsa, Afshin Lash, James P. Rahman, Mahboob Hsu, Chi-yuan Weir, Matthew R. Chen, Jing Anderson, Amanda Grams, Morgan E. Surapaneni, Aditya Coresh, Josef Li, Hongzhe Kimmel, Paul L. Vasan, Ramachandran S. Feldman, Harold Segal, Mark R. Ganz, Peter |
author_sort | Dubin, Ruth F. |
collection | PubMed |
description | Progression of chronic kidney disease (CKD) portends myriad complications, including kidney failure. In this study, we analyze associations of 4638 plasma proteins among 3235 participants of the Chronic Renal Insufficiency Cohort Study with the primary outcome of 50% decline in estimated glomerular filtration rate or kidney failure over 10 years. We validate key findings in the Atherosclerosis Risk in the Communities study. We identify 100 circulating proteins that are associated with the primary outcome after multivariable adjustment, using a Bonferroni statistical threshold of significance. Individual protein associations and biological pathway analyses highlight the roles of bone morphogenetic proteins, ephrin signaling, and prothrombin activation. A 65-protein risk model for the primary outcome has excellent discrimination (C-statistic[95%CI] 0.862 [0.835, 0.889]), and 14/65 proteins are druggable targets. Potentially causal associations for five proteins, to our knowledge not previously reported, are supported by Mendelian randomization: EGFL9, LRP-11, MXRA7, IL-1 sRII and ILT-2. Modifiable protein risk markers can guide therapeutic drug development aimed at slowing CKD progression. |
format | Online Article Text |
id | pubmed-10564759 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-105647592023-10-12 Proteomics of CKD progression in the chronic renal insufficiency cohort Dubin, Ruth F. Deo, Rajat Ren, Yue Wang, Jianqiao Zheng, Zihe Shou, Haochang Go, Alan S. Parsa, Afshin Lash, James P. Rahman, Mahboob Hsu, Chi-yuan Weir, Matthew R. Chen, Jing Anderson, Amanda Grams, Morgan E. Surapaneni, Aditya Coresh, Josef Li, Hongzhe Kimmel, Paul L. Vasan, Ramachandran S. Feldman, Harold Segal, Mark R. Ganz, Peter Nat Commun Article Progression of chronic kidney disease (CKD) portends myriad complications, including kidney failure. In this study, we analyze associations of 4638 plasma proteins among 3235 participants of the Chronic Renal Insufficiency Cohort Study with the primary outcome of 50% decline in estimated glomerular filtration rate or kidney failure over 10 years. We validate key findings in the Atherosclerosis Risk in the Communities study. We identify 100 circulating proteins that are associated with the primary outcome after multivariable adjustment, using a Bonferroni statistical threshold of significance. Individual protein associations and biological pathway analyses highlight the roles of bone morphogenetic proteins, ephrin signaling, and prothrombin activation. A 65-protein risk model for the primary outcome has excellent discrimination (C-statistic[95%CI] 0.862 [0.835, 0.889]), and 14/65 proteins are druggable targets. Potentially causal associations for five proteins, to our knowledge not previously reported, are supported by Mendelian randomization: EGFL9, LRP-11, MXRA7, IL-1 sRII and ILT-2. Modifiable protein risk markers can guide therapeutic drug development aimed at slowing CKD progression. Nature Publishing Group UK 2023-10-10 /pmc/articles/PMC10564759/ /pubmed/37816758 http://dx.doi.org/10.1038/s41467-023-41642-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Dubin, Ruth F. Deo, Rajat Ren, Yue Wang, Jianqiao Zheng, Zihe Shou, Haochang Go, Alan S. Parsa, Afshin Lash, James P. Rahman, Mahboob Hsu, Chi-yuan Weir, Matthew R. Chen, Jing Anderson, Amanda Grams, Morgan E. Surapaneni, Aditya Coresh, Josef Li, Hongzhe Kimmel, Paul L. Vasan, Ramachandran S. Feldman, Harold Segal, Mark R. Ganz, Peter Proteomics of CKD progression in the chronic renal insufficiency cohort |
title | Proteomics of CKD progression in the chronic renal insufficiency cohort |
title_full | Proteomics of CKD progression in the chronic renal insufficiency cohort |
title_fullStr | Proteomics of CKD progression in the chronic renal insufficiency cohort |
title_full_unstemmed | Proteomics of CKD progression in the chronic renal insufficiency cohort |
title_short | Proteomics of CKD progression in the chronic renal insufficiency cohort |
title_sort | proteomics of ckd progression in the chronic renal insufficiency cohort |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564759/ https://www.ncbi.nlm.nih.gov/pubmed/37816758 http://dx.doi.org/10.1038/s41467-023-41642-7 |
work_keys_str_mv | AT dubinruthf proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT deorajat proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT renyue proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT wangjianqiao proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT zhengzihe proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT shouhaochang proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT goalans proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT parsaafshin proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT lashjamesp proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT rahmanmahboob proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT hsuchiyuan proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT weirmatthewr proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT chenjing proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT andersonamanda proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT gramsmorgane proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT surapaneniaditya proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT coreshjosef proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT lihongzhe proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT kimmelpaull proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT vasanramachandrans proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT feldmanharold proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT segalmarkr proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT ganzpeter proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT proteomicsofckdprogressioninthechronicrenalinsufficiencycohort AT proteomicsofckdprogressioninthechronicrenalinsufficiencycohort |